Company intelligence / Profile preview

CourageAS Biotherapeutics

United States

Ownership: Private
Development stage: Other

Overview

As of early 2025, no published clinical results; preclinical data supports advancement to IND-enabling studies. The company aims to restore endogenous UBE3A expression using innovative non-viral genome editing technology. Clinical trials are anticipated but have not commenced or reported results publicly.

Therapeutic areas: Neurology
Modalities: Gene editing therapyNon-viral gene-editing technology
Industry: Biotech

Partnerships

CourageneFoundation for Angelman Syndrome Therapeutics (FAST)AS²Bio accelerator

Beyond the preview

Go deeper on CourageAS Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CourageAS Biotherapeutics.

Explore the full profile